EUVIMEDEUVIMED entdecken
Open Access

STAT3 expression in brain metastases from breast cancer is correlated with molecular subtype and impacts clinical outcome

Alessia Pellerino iD, Neibla Priego iD, Luca Bertero iD, Alessia Andrea Ricci iD, Luca Mangherini iD, Francesco Bruno iD, Alessandra Beano, Gloria Mittica, Marinella Mistrangelo, Diego Garbossa iD, Joaquim Bosch-Barrera iD, Paola Cassoni iD und 4 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noaf187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Alessia Pellerino und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuro-Oncology, Department of Neuroscience "Rita Levi Montalcini," University and City of Health and Science Hospital, Turin, Italy. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Brain Neoplasms, Biomarkers, Tumor, Breast Neoplasms. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: ERC CoG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A high pSTAT3 expression in reactive astrocytes surrounding brain metastases (BrM) promotes tumor growth in preclinical models. The impact of STAT3 expression on outcome of patients with BrM from breast cancer is unknown.

Methods

The expression of pSTAT3 in reactive astrocytes of 100 resected BrM from breast cancer was investigated by immunohistochemistry and correlated with molecular subtypes, risk of intracranial recurrence and progression-free survival. To explore whether clinical findings could be replicated in preclinical models, we used two human BrM cell lines (triple-negative MDA231 and HER2-positive HCC1954-), and evaluated pSTAT3 expression on established BrM.

Results

High pSTAT3 expression in reactive astrocytes was detected in 57% of BrM, and prevailed in triple-negative (80.9%) over HER2-positive (43.2%) and luminal (33.3%) metastases (P = .002). A different pSTAT3 expression was confirmed in animal models: as it was detected in 50% of reactive astrocytes in triple-negative MDA231 BrM lesions compared with 13% in HER2-positive HCC1954—BrM lesions (P = .0001). Patients with high pSTAT3 expression in BrM displayed higher intracranial recurrence rate (66.7 vs 33.3%) (P = .0353), and shorter intracranial PFS (9 months vs 28 months) (P = .0002), and this finding was significant for triple-negative patients only (P = .0008).

Conclusions

This study indicates that STAT3 expression prevails in reactive astrocytes surrounding triple-negative BrM in comparison to HER2-positive and luminal BrM, and these findings mirror those observed in animal models. A high STAT3 expression correlates with higher risk of intracranial recurrence and shorter progression-free survival, particularly in patients with triple-negative BrM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT3 Transcription FactorBrain NeoplasmsBiomarkers, TumorBreast NeoplasmsNeoplasm Recurrence, LocalHumansFemaleMiddle AgedAnimalsPrognosisAgedAstrocytesAdultErb-b2 Receptor Tyrosine KinasesSurvival RateMiceFollow-Up Studies

Stichwörter der Autor:innen

STAT3 expressionbrain metastasesbreast cancerreactive astrocytessilibinin

Substanzen

STAT3 Transcription FactorSTAT3 protein, humanBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Division of Neuro-Oncology, Department of Neuroscience "Rita Levi Montalcini," University and City of Health and Science Hospital, Turin, Italy.
  • Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Pathology Unit, Department of Medical Sciences, University and City of Health and Science Hospital, Turin, Italy.
  • Breast Medical Oncology, Department of Oncology, City of Health and Science Hospital, Turin, Italy.
  • Neurosurgery Unit, Department of Neuroscience "Rita Levi Montalcini," University and City of Health and Science Hospital, Turin, Italy.
  • Department of Medical Sciences, Medical School, University of Girona, Girona, Spain.

ORCID-Profile: Alessia Pellerino, Neibla Priego, Luca Bertero, Alessia Andrea Ricci, Luca Mangherini, Francesco Bruno, Diego Garbossa, Joaquim Bosch-Barrera, Paola Cassoni, Manuel Valiente, Riccardo Soffietti, Roberta Rudà

Förderung

  • ERC CoG

Zitieren

APA

Pellerino, A., Priego, N., Bertero, L., Ricci, A. A., Mangherini, L., Bruno, F., Beano, A., Mittica, G., Mistrangelo, M., Garbossa, D., Bosch-Barrera, J., Cassoni, P., RENACER, Valiente, M., Soffietti, R., & Rudà, R. (2025). STAT3 expression in brain metastases from breast cancer is correlated with molecular subtype and impacts clinical outcome. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf187

Vancouver

Pellerino A, Priego N, Bertero L, Ricci AA, Mangherini L, Bruno F, et al. STAT3 expression in brain metastases from breast cancer is correlated with molecular subtype and impacts clinical outcome. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf187

BibTeX
@article{Pellerino2025,
  author = {Pellerino, Alessia and Priego, Neibla and Bertero, Luca and Ricci, Alessia Andrea and Mangherini, Luca and Bruno, Francesco and Beano, Alessandra and Mittica, Gloria and Mistrangelo, Marinella and Garbossa, Diego and Bosch-Barrera, Joaquim and Cassoni, Paola and RENACER, RENACER and Valiente, Manuel and Soffietti, Riccardo and Rudà, Roberta},
  title = {STAT3 expression in brain metastases from breast cancer is correlated with molecular subtype and impacts clinical outcome},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noaf187}
}
Kostenlos starten →